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A SUMMARy Of OUTCOMES fOR THE Per-Protocol POPUlATION
INTRODUCTION
The Research Outcome Study in Ireland (ROSIE) is the first national, prospective, longitudinal, multi-site drug treatment 
outcome study in the country. The National Advisory Committee on Drugs (NACD) commissioned this research in 
2002 as required by the National Drugs Strategy Action 99. The aim of the study was to recruit and follow opiate users 
entering treatment over a period of time documenting the changes observed. The contract was awarded to Dr. Catherine 
Comiskey and the National University of Ireland, Maynooth.
The study recruited 404 opiate users entering treatment. Outcomes presented in this document are for the 289 individuals 
who completed all three interviews -baseline interview at intake and the follow-up interviews at 1-year and 3-years. 
Individuals who complete all planned aspects of a study are defined as the per-protocol group. An analysis of  
the data from the per-protocol group provides insights into experiences between 1 and 3 years post treatment intake. 
Outcomes for the per-protocol group at intake, 1-year and 3-years for drug use, involvement in crime, injecting-related 
behaviour, physical and mental health and social functioning are presented in this paper. Statistically significant differences 
are given emphasis in this document. 
KEy MESSAGES
(only statistically significant reductions are noted below,  
figures rounded) 
l 404 opiate users were recruited to ROSIE at treatment intake.  
97% (n=392) of the original interviewees were located at 3-years  
and 88% (n=357) successfully completed their final interview. 
l 71.5% (n=289) completed interviews at all three time points and these 
are defined as the per-protocol group.
l 1.5% (n=6) of the study population had died at the 3-year follow-up 
interview stage. 0.5% (n=2) of the study population had died at the  
1-year time point.
l 70% (n=201/289) of the per-protocol group were in some form of 
treatment at 3-years. 60% (n=173/289) were in methadone treatment 
at 3-years.
l Overall, significant reductions in heroin use were observed in the  
per-protocol group at 1-year and sustained at 3-years (from 81% to  
47% and 47% respectively). Reductions in cannabis use, cocaine use  
and polydrug use were achieved at 1-year and sustained at 3-years.
l 29% (n=85) of the per-protocol population were abstinent from all illegal 
drugs at 3-years. The largest improvement was at 1-year and sustained at 
3-years (from 7% to 29% and 29% respectively).
l Whilst significant reductions in injecting drug use were observed in the 
per-protocol population 3-years after treatment intake this had mainly 
occurred by 1-year and little change was observed in injecting-related risk 
behaviour across all periods.
l Significant reductions in criminal activity were observed in the per-protocol 
population at 1-year and these levels were sustained at 3-years.
l Results in the per-protocol population at 1-year and 3-years for a range  
of physical and mental health symptoms were mixed. 
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SUMMARy All OUTCOMES
DRUG USE OUTCOMES
l	 Heroin use: There was a reduction in the overall percentage 
of individuals reporting heroin use, from 80.6% at intake  
to 46.7% at 1-year. Similar usage levels were reported at  
3-years. The frequency of heroin use also significantly 
reduced from 42.3 days in the last 90 days at intake, to 15.2 
days at 1-year. There was a significant increase from 15.2 
days at 1-year to 20.1 days at 3-years; however, this was still 
significantly lower than the frequency of usage at intake. The 
amount of heroin used also reduced significantly between 
intake (0.7g) and 1-year (0.2g), with little change between 
1-year and 3-years.
l	 Other drug use: Reductions in the reported use of all 
target drugs (non-prescribed methadone, non-prescribed 
benzodiazepines, cocaine including crack, cannabis and 
alcohol) were seen at 1-year. The proportion reporting the 
use of these target drugs at 3-years was similar to 1-year, 
with the exception of non-prescribed benzodiazepines which 
increased significantly between 1- and 3-years. However, the 
proportions reporting use of non-prescribed benzodiazepines 
were significantly lower at 3-years than at treatment intake.
• Reported use of cannabis reduced significantly from 
65.3% at treatment intake to 52.8% at 1-year, with a 
further non-significant decrease to 50.7% at 3-years.
• Reported use of cocaine, including crack, reduced 
significantly from 48.4% at treatment intake to 22.8% at 
1-year, with a further non-significant decrease to 21.3% 
at 3-years.
• Reported use of non-prescribed benzodiazepines 
reduced significantly from 43.7% at treatment intake 
to 23.2% at 1-year, with a significant increase at 
3-years to 30.2%. This reported usage was still 
significantly lower than that reported at treatment 
intake.
• Reported use of non-prescribed methadone reduced 
significantly from 44.4% at treatment intake to 14.2%  
at 1-year, with levels at 1-year and 3-years (12.5%) more 
or less the same.
• Reported use of alcohol reduced significantly from 56.9% 
at treatment intake to 43.9% at 1-year, with levels at  
1-year and 3-years (43.9%) approximately the same. 
• Reductions in the frequency (mean days) of use of 
all target drugs were observed between intake and 
1-year. At 3-years, this reduced frequency of use had 
been maintained for three of the target drugs. However, 
cannabis use had a further significant reduction, 
while frequency of heroin and benzodiazepines 
(non-prescribed) use each increased significantly. 
The frequency of usage observed at 3-years was still 
significantly lower than at intake.
• The overall percentage of individuals reporting polydrug 
use1 decreased significantly from 77.5% at treatment 
intake to 49.5% at 1-year, with a further non-significant 
decrease to 45.3% at 3-years.
l	 Drug abstinence: Significant increases in the proportion 
of individuals reporting abstinence from all drugs (excluding 
alcohol and prescribed methadone) were observed 
between intake (6.7%) and 1-year (28.8%), with a 
further non-significant increase observed between 1-year 
and 3-years (29.4%).
INVOlVEMENT IN CRIME OUTCOMES
l	 The proportion of participants reporting involvement in all 
12 categories of crime fell significantly between intake and 
1-year. Ten of these 12 categories sustained these changes 
at 3-years, with the remaining two categories lower, although 
not significantly lower, than at intake.
RISK BEHAVIOUR OUTCOMES
l	 Significant improvements were evident in the proportions 
injecting any drug, the number of days injecting any drug, 
and number of times injecting on a typical drug-taking day  
in the last three months, between baseline and 1-year.  
These improvements were sustained at 3-years.
l	 At treatment intake, participants reported low rates of 
borrowing and lending of used injecting equipment.  
There were no significant changes in these behaviours  
across any time points.
l	 There were no significant changes in overdose rates.
PHySICAl AND MENTAl HEAlTH OUTCOMES
l	 A significant reduction in five of the ten physical health 
symptoms was observed between intake and 1-year. Three 
of these five reductions were sustained at 3-years, with one 
of the symptoms increasing to similar levels observed at 
intake and the remaining symptom increasing significantly  
at 3-years but still significantly lower at 3-years than at 
intake. Of the remaining five physical health symptoms, one 
was found to have a significant reduction in the proportion 
reporting experiencing the symptom at 3-years than at 
intake, while one was found to have a significant increase 
between 1-year and 3-years.
1  The definition of polydrug use is concurrent drug use, meaning at least two substances are used during the same time period (NACD, 2007).  
We define polydrug use as the use of two or more illegal substances in the last 90 days, the time period for which drug use data was collected.
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l	 A significant reduction in three of the five anxiety symptoms 
was observed between intake and 1-year; however, each 
of these symptoms increased significantly between 1-year 
and 3-years, returning to levels observed at intake. Further, 
one of the remaining two anxiety symptoms also increased 
significantly between 1-year and 3-years.
l	 A significant reduction in three of the five depressive 
symptoms was noted between intake and 1-year, with  
two of these three symptoms sustaining this reduction  
at 3-years. Of the remaining two depression symptoms,  
one reduced significantly between intake and 3-years.
TREATMENT STATUS
l	 70% were in some form of treatment at 3-years.
l	 Of those in methadone treatment at baseline, 2.6% 
completed their index baseline treatment by 3-year follow-
up, with 41.2% still attending their index treatment and 
19.6% not completing their baseline methadone treatment. 
The remaining clients who were in methadone treatment  
at baseline transferred to either another treatment modality 
or setting.
EMPlOyMENT AND TRAINING
l	 Proportions currently working, employed at some time in the 
last three months, and on a training course over the last six 
months all increased significantly at each time point. 
l	 The proportion who described themselves as usually not 
working fell significantly between intake and 1-year, with  
a further non-significant decrease at 3-years.
ACCOMMODATION
l	 Proportions living in the family home decreased significantly 
between intake and 1-year and this was sustained at  
3-years, while the proportion owning their own house or  
flat or in rental accommodation increased significantly 
between intake and 1-year and these levels were sustained 
at 3-years.
l	 The proportion in a drug treatment residence decreased 
significantly between intake and 1-year and a further 
significant decrease was observed at 3-years.
l	 The proportion in insecure accommodation (including 
participants living in hostels, shelters, B&B’s or with no fixed 
abode) decreased significantly between intake and 3-years.
CONTACT WITH SERVICES
l	 Of the four health services investigated, visiting a non-
methadone GP was the only service where a significant 
increase in usage was observed between intake and 1-year. 
l	 Contact with two of the four health services increased 
significantly between intake and 3-years.
l	 Of the four social support services investigated, usage of 
three of the services: social services, employment, training or 
education services and housing services increased significantly 
between intake and 1-year, with usage levels at 3-years also 
significantly higher than at intake for employment, training 
or education services and housing services. However, the 
proportion in contact with employment, training or education 
services was significantly lower at 3-years than at 1-year.

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METHODOlOGy
1. STUDy DESIGN
ROSIE is a longitudinal observational study, which follows 
participants from the point of commencing a new treatment 
episode (treatment intake) and monitors progress at time 
anchored points; at intake, then at 1-year and 3-years 
after treatment intake. Between September 2003 and July 
2004, the ROSIE study recruited 404 opiate users. The 
majority entered one of three index treatments: methadone 
maintenance/reduction (53.2%, n=215), structured 
detoxification (20%, n=81) and abstinence-based treatment 
(20.3%, n=82) and the remainder were recruited from 
needle exchanges (6.4%, n=26). These modalities were part 
of the tender brief from the NACD as they were considered 
to represent the most widely implemented interventions for 
opiate users in Ireland.
The 404 ROSIE study participants were recruited from both 
inpatient (hospitals, residential programmes and prisons) 
and outpatient settings (community-based clinics, health 
board clinics and GPs). Participants had to be over 18 years, 
commencing a new treatment episode, prepared to consent to 
the tracking/follow-up procedures, and willing to provide locator 
information. Treatment agencies participating in the study were 
purposively (not randomly) sampled to reflect drug treatment 
in Ireland and the known geographical spread of provision and 
range of services. In total, 44 agencies providing approximately 
54 services located in rural, urban and inner-city areas of Ireland 
were involved in the study. In addition, a Research Advisory 
Group was established by the NACD to support and monitor 
the research project. 
Participants were interviewed at the three time periods using a 
pre-prepared interview schedule, which examined key outcome 
measures including:
l	 Drug use (drug type, frequency, and quantity of drug use);
l	 General health (a 10-point physical and mental health 
assessment);
l	 Social functioning (employment, accommodation, 
involvement in crime);
l	 Harm (injecting behaviour & experience of overdose); and
l	 Mortality (participant/contact feedback and checking non 
followed-up participants against the General Death Register).
In addition to a lifetime measure, measures were taken for 
behaviours in the 90 days preceding interviews except for 
injecting related risk behaviour variables where use in the last 
30 days was used. Individuals were asked about their use of 
16 substances. This document focuses on the seven most 
frequently reported problem drugs – referred to as target 
drugs (heroin, non-prescribed methadone, non-prescribed 
benzodiazepines, cocaine powder, crack cocaine, cannabis 
and alcohol)2 and reports changes in use patterns at 3-years.  
For more detailed information on lifetime use and use at 
intake, see Cox & Comiskey (2007) and the baseline ROSIE 
report (http://www.nacd.ie/publications/treatment_rosie_
summary.html). 
2. fOllOW-UP
Follow-up of participants was assisted by the provision of 
at least four contacts (locator information) for each person 
(including a drug treatment contact, family member, GP & 
others). A small remuneration was provided at 1-year and at 
3-year follow-up to acknowledge the ongoing participation of 
the individual in the study. 
As a result of extensive tracking efforts, 97% of all original 
participants were located at 3-year follow-up (n=392) and 
88.4% (n=357) of participants successfully completed 
interviews. This is an improvement on the 12-month follow-up 
where 75% (n=305) of the original cohort completed full 
interviews. A total of 289 participants completed interviews 
at each stage – intake, 1-year and 3-years. At 3-years, a total 
of 3.5% (n=14) of participants did not wish to be interviewed, 
3% (n=12) were not located and 1.5% (n=6) of participants 
were deceased, with 0.2% (n=1) in a coma. 3.5% (n=14) 
were located but not interviewed and of these participants, four 
individuals were living in another country and eight individuals 
were on a methadone programme. None of these individuals 
were in prison.
The follow-up rate in the study for participants who were 
interviewed and the location rate for those who were either 
located or interviewed at the 3-year follow-up time point 
exceeded all international standards achieved to date and 
completely reversed the usual trend of decreasing follow-up 
rates as time progresses.
Within ROSIE, the 3-year mortality rate was 1.5% (95% 
C.I.3: 0.5% - 3.2%). Six of the 404 participants died between 
the start of recruitment in September 2003 and the end of  
3-year follow-up interview period in July 2007. Two of these 
deaths occurred within the 1-year follow-up period. The 
mortality rate for the population (2/404) at 1-year was  
0.5% (95% C.I.: 0.06% - 1.78%). 
2 In some instances, where appropriate, data with respect to cocaine powder and crack cocaine were combined for analysis.
3 C.I.: Confidence Interval.
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3. STUDy lIMITATIONS
1.  Although the findings presented here highlight positive 
outcomes for the per-protocol population they do not 
indicate a direct causal relationship between the treatment 
received and the outcomes observed.
2. The study did not randomly allocate participants to 
treatment settings/modality or employ a control group 
(drug users with similar profile not attending the index 
treatment).
3.  Any individual behaviour change is the result of the 
interaction of three factors, the person, the environment 
and the intervention, all of which can influence outcomes 
but could not be controlled for in this study.
4. UNDERSTANDING THIS PAPER
The reader should be aware that the data presented in this 
paper includes all valid responses provided by the cohort  
who completed all three interviews: baseline, 1-year and  
3-year. The statistical comparisons are made on matched data 
or dependent pairs, that is, only individuals who provided 
valid answers to each question at each time point under 
comparison were included in the analysis. Missing data 
were handled by excluding the cases from the particular 
analysis4. In terms of presenting statistical comparisons, 
time points with a common letter subscript are statistically 
significant while those with no common letter subscript are 
not statistically significant. Changes in all categorical variables 
were analysed using the McNemar test. Paired sample t-tests 
were performed when comparing sample means at two time 
points. Statistical significance can only be stated when tests 
have been carried out on the data to establish the degree of 
confidence with which it can be inferred that the differences 
in the observed findings are true and not due to sampling or 
other error. This is reported at a 5% level of probability, that 
is, a p-value of 0.05 or less is used for statistical significance.
It was noted within the analysis of the ROSIE per-protocol 
group that results observed for the full cohort were reflected 
by the per-protocol group thus providing additional supporting 
evidence for the positive outcomes found and presented in 
Comiskey, Kelly and Stapleton (2008). The corresponding 
outcomes for the full cohort at 3-years are presented in 
ROSIE Findings 5.
International drug treatment outcome studies typically 
measure levels of drug use, health, crime, mortality and social 
functioning variables to monitor the impact of treatments for 
problem drug use (see e.g. Gossop et al, 2002; Gossop et 
al, 2003; Hubbard et al, 2003; Darke et al, 2006; Schifano, 
2006; Teesson et al, 2006).
Within this findings paper, in order to keep tables of data 
clear and easy to read, changes from intake to 1 and  
3-years for males and for females are not reported. Details 
on the effects of gender on outcomes observed at 3-years 
will be presented in the forthcoming Findings on predictors 
of outcomes. In addition gender is also addressed within 
Findings on polydrug use.
4  The percentage totals presented in Tables 1-15 are calculated on the basis of valid responses.
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DRUG USE OUTCOMES
International drug treatment outcome studies typically 
measure levels of drug use, health, crime, mortality and social 
functioning variables to monitor the impact of treatments for 
problem drug use (see e.g. Gossop et al, 2002; Gossop et 
al, 2003; Hubbard et al, 2003; Darke et al, 2006; Schifano, 
2006; Teesson et al, 2006). The ROSIE analysis examined 
changes in:
n	 The percentage of individuals reporting the use of each  
drug type.
n	 Drug using frequency (mean number of drug using days 
over the previous 90 days).
n	 Average quantity of each drug consumed on a typical  
drug using day.
n	 Drug abstinence rates.
Table 1 shows the proportions using each target drug as 
reported at treatment intake, 1-year and 3-years. Reductions in 
the proportions using each drug, proportions using alcohol and 
the proportions engaging in polydrug use between treatment 
intake and 1-year were found to be significant. These reduced 
levels were maintained between 1-year and 3-years with the 
exception of benzodiazepines, which displayed a significant 
rise in the proportion using between 1-year and 3-years. 
However, the proportion using at 3-years was still significantly 
lower than at intake to treatment.
Table 1:  Drug use at treatment intake,  
1-year and 3-years
Drug use in 
last 90 days
Intake 1-year 3-years
% n % n % n
Heroin 80.6ab 229 46.7a 135 46.7b 135
Cannabis 65.3ab 175 52.8a 151 50.7b 146
Cocaine  
including crack
48.4ab 140 22.8a 66 21.3b 61
1Benzodiazepines 43.7ab 124 23.2ac 67 30.2bc 87
2Methadone 44.4ab 127 14.2a 41 12.5b 36
Alcohol 56.9ab 153 43.9a 126 43.9b 126
3Polydrug 
use
77.5ab 224 49.5a 143 45.3b 131
1 Refers to non-prescribed benzodiazepines.
2  Refers to non-prescribed methadone.
3  Polydrug use defined as using two or more illegal drugs in the last 
90 days.
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
Table 2 displays the mean number of days on which each 
drug was used as reported at each of the three time points: 
treatment intake, 1-year and 3-years. For each drug type  
as well as alcohol, analysis revealed significant reductions  
in the mean days used between treatment intake and  
1-year follow-up. Further significant reductions were reported 
between 1-year and 3-years for cannabis. For both heroin 
and benzodiazepine usage, significant increases were found 
for the mean number of days used between 1-year and  
3-years, however there was still a significant reduction 
between intake and 3-years for the usage of these two drugs.
Table 2:  Drug using days at treatment intake,  
1-year and 3-years
Mean days 
used in last  
90 days
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Heroin 42.3 (35.3)ab 15.2 (27.6)ac 20.1 (32.3)bc
Cannabis 40.4 (40.3)ab 32.1 (39.8)ac 25.4 (36.0)bc
1Benzodiazepines 15.5 (29.3)ab 5.3 (15.9)ac 9.2 (23.2)bc
2Methadone 13.2 (24.6)ab 4.0 (16.1)a 2.0 (8.7)b
Cocaine  
including crack
9.0 (19.8)ab 3.8 (13.9)a 3.6 (13.5)b
Alcohol 13.6 (23.2)ab 9.3 (20.0)a 9.7 (20.4)b
1  Refers to non-prescribed benzodiazepines.
2  Refers to non-prescribed methadone.
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
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Table 3 illustrates the mean quantity of each drug consumed 
on a typical drug using day as reported at treatment intake,  
1-year and 3-years. Analysis revealed a significant reduction 
in the average quantity of all drugs consumed between 
treatment intake and 1-year, with the exception of cannabis 
which significantly reduced between intake and 3-years. 
These reductions were mostly maintained between 1-year 
and 3-years with the exception of benzodiazepines. For this 
drug, a significant increase was observed between 1-year  
and 3-years with levels of usage returning to levels similar  
to those observed at intake.
Table 3:  Mean quantity of drugs consumed at 
treatment intake, 1-year and 3-years
Mean amounts 
used per day in 
last 90 days
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Heroin (grams) 0.7 (0.8)ab 0.2 (0.6)a 0.2 (0.4)b
Cannabis 
(joints)
7.1 (15.9)b 5.6 (21.3) 3.8 (11.4)b
Cocaine (excluding 
crack) (grams) 
0.9 (2.3)ab 0.3 (1.1)a 0.3 (0.8)b
1Benzodiazepines 
(mg)
38.4 (107.5)a 23.8 (124.1)ac 40.7 (147.1)c
2Methadone (ml) 25.4 (39.2)ab 7.5 (27.8)a 7.6 (24.8)b
Alcohol (units) 8.5 (12.4)ab 6 (14.2)a 5.6 (10)b
1 Refers to non-prescribed benzodiazepines.
2 Refers to non-prescribed methadone.
a – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years  
are statistically significant
Crack cocaine was excluded due to inconsistency in how the data  
was reported.
These cost figures are based on: 
Heroin: 1 bag costing €20 and containing on average 0.113g  
 at  treatment intake, 1 bag containing on average 0.1g  
 costing €20 at 3-years.
Cocaine: 1 gram costing €110 at treatment intake, the same  
 quantity costing €70 at 3-years.
Cannabis: 1 ounce costing €110 at treatment intake, the  
 same quantity costing €198.45 at 3-years (or a joint  
 costing approximately 39c at treatment intake, and  
 approximately 70c at 3-years).
Source: Costs advised through private communication  
(O’Brien, An Garda Síochána).
Table 4 shows the proportions that are drug free (not using  
any illegal drugs) at treatment intake, 1-year and 3-years.  
A significant increase in the drug free proportions was evident 
between treatment intake and 1-year and this increase was 
sustained at 3-years.
Table 4:  Drug free at treatment intake,  
1-year and 3-years
Drug free in 
last 90 days
Intake 1-year 3-years
% n % n % n
Drug free (not 
using any illicit drug 
excluding alcohol 
and prescribed 
methadone) 
6.7 ab 19 28.8a 83 29.4b 85
a – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
MORTAlITy RATE
Mortality is not analysed for the per-protocol population, since, 
by definition, the cohort has completed all three interviews. 
However, page four gives a summary of the mortality rate and 
further details can be found in ROSIE Findings 5.
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INVOlVEMENT IN CRIME
Table 5 presents the proportion of individuals reporting 
participation in each category of crime at treatment intake, 
1-year and 3-years. Between intake and 1-year, a significant 
reduction in the proportion committing each type of crime 
was noted. With the exceptions of theft from a vehicle and 
criminal damage, each of the crimes was committed by a 
significantly lower proportion of the population at 3-years 
than at intake, with levels at 3-years similar to those at 1-year. 
The proportion reporting theft from a vehicle, and committing 
criminal damage at 3-years was slightly higher than at 1-year 
and not significantly lower than at intake. 
Table 5:  Crimes committed at treatment intake,  
1-year and 3-years
Crime 
committed in 
last 90 days
Intake 1-year 3-years
% n % n % n
Selling/supplying 
drugs
31.0ab 81 10.8a 31 10.8b 31
Theft from a 
person
11.8ab 31 2.5a 7 1.7b 5
Theft from house/
home
6.9ab 18 2.5a 7 3.1b 9
Theft from shop/
commercial 
property
19.1ab 50 8.3a 24 7.6b 22
Theft from a 
vehicle
8.0a 21 3.2a 9 4.2 12
Theft of a 
vehicle
7.9ab 21 1.8a 5 2.1b 6
Handling stolen 
goods
26.2ab 68 7.3a 21 10.4b 30
Fraud/forgery/
deception
10.8ab 28 1.4a 4 2.8b 8
Assault 7.7ab 20 2.8a 8 2.8b 8
Criminal damage 6.9a 18 1.7a 5 3.8 11
Soliciting 4.6ab 12 1.1a 3 0.7b 2
Breach of the 
peace
7.7ab 20 1.8a 5 2.8b 8
a – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
INjECTING-RElATED RISK BEHAVIOUR
Table 6 shows injecting drug use in the last 30 days as 
reported at treatment intake, 1-year and 3-years. Analysis 
showed significant reductions in the proportions injecting 
any drug, injecting heroin, injecting cocaine, and injecting 
benzodiazepines from treatment intake to 1-year. The 
observed proportions injecting remained relatively constant 
between 1-year and 3-years.
Table 6:  Injecting drug use at treatment intake,  
1-year and 3-years
In the last 
30 days
Intake 1-year 3-years
% n % n % n
Injected any 
drug
45.6ab 131 28.7a 83 26.7b 77
Injected 
heroin
43.3ab 125 26.3a 76 25.0b 72
Injected 
cocaine 
powder
21.1ab 61 9.0a 26 8.0b 23
Injected 
benzodiazepines
12.1ab 35 2.8a 8 4.5b 13
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
Table 7 displays the mean number of days injected and 
mean number of times injected per day as reported at 
treatment intake, 1-year and 3-years. Analysis revealed 
significant reductions in both the mean number of days and 
the mean number of times injecting per day between intake 
and 1-year. These reported levels remained more or less the 
same between 1- and 3-years.
Table 7:  Mean days/times injected at treatment 
intake, 1-year and 3-years
In the last  
30 days
Intake 1-year 3-years
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Days 
injected
20.8 (32.3)ab 8.9 (22.3)a 10.4 (25.7)b
Times 
injected on 
typical day
1.8 (4.2)ab 0.8 (2.6)a 0.8 (1.8)b
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
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Table 8 presents data on injecting-related risk behaviour 
at treatment intake, 1-year and 3-years. At intake, a low 
proportion of participants reported injecting-related risk 
behaviour (i.e. the borrowing/lending, reusing of used 
injecting equipment). The proportions engaging in injecting-
related risk behaviour did not change significantly.
Table 8:  Injecting-related risk behaviour at 
treatment intake, 1-year and 3-years
In the last  
30 days
Intake 1-year 3-years
% n % n % n
Borrowed used 
needle/syringe 
4.5 12 2.8 8 3.5 10
Lent used 
needle/syringe
3.8 10 3.5 10 3.5 10
Re-used own 
needle/syringe
14.7 34 12.4 35 16.0 45
OVERDOSE
Table 9 presents data on overdoses within the last 90 days 
as reported at treatment intake, 1-year and 3-years. The 
proportions did not change significantly during the study, 
although a small reduction in the proportion reporting 
overdose was noted between intake and 1-year and a slight 
increase was observed between 1- and 3-years.
Table 9:  Overdose at treatment intake,  
1-year and 3-years
In the last  
90 days
Intake 1-year 3-years
% n % n % n
Overdose 7.2 20 3.9 11 5.2 15
PHySICAl AND MENTAl HEAlTH 
OUTCOMES
Table 10 presents data on physical health symptoms 
experienced over the last three months as reported at 
treatment intake, 1-year and 3-years. Analysis revealed 
a significant decrease in proportions experiencing five 
symptoms (poor appetite, tiredness/fatigue, joint/bone pains, 
muscle pains, tremors/shakes) between treatment intake 
and 1-year, with poor appetite, joint/bone pains and muscle 
pains each maintaining this decrease at 3-years. Tiredness/
fatigue increased significantly between 1-year and 3-years 
with the proportions reporting this symptom at 3-years 
similar in size to the proportions reporting the symptom at 
intake. The proportion reporting tremors/shakes at 3-years 
increased significantly from 1-year but was still significantly 
lower than the proportion reporting the symptom at baseline. 
The proportion of clients reporting nausea/feeling sick 
decreased significantly between intake and 3-years, while the 
proportions reporting numbness/tingling symptoms increased 
significantly between 1-year and 3-years. 
Table 10:  Number and proportion experiencing 
physical health symptoms at treatment intake, 
1-year and 3-years
Symptoms 
experienced over 
last 90 days
Intake 1-year 3-years
% n % n % n
Poor appetite 72.3ab 193 60.1a 167 55.8b 158
Tiredness/
fatigue
72.4a 194 62.8ac 174 70.0c 198
Nausea/ 
feeling sick
40.1b 107 32.5 91 33.1b 94
Stomach pains 37.2 99 33.6 94 37.9 107
Difficulty 
breathing
29.9 79 24.6 69 29.0 82
Chest pains 22.2 59 18.2 51 19.4 55
Joint/bone pains 37.5ab 100 25.4a 71 26.2b 74
Muscle pains 34.3ab 91 23.6a 66 23.6b 67
Numbness/
tingling
22.5 60 17.1c 48 28.5c 80
Tremors/shakes 28.8ab 75 15.8ac 44 22.9bc 65
a  – matching ‘a’ denotes changes from intake to 1-year  
are statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years  
are statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years  
are statistically significant
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Table 11 presents data on mental health symptoms 
experienced over the last three months as reported at 
treatment intake, 1-year and 3-years. Analysis revealed a 
significant decrease in proportions experiencing each of three 
different symptoms of anxiety (feeling tense, suddenly scared 
for no reason, nervousness/shakiness inside) between 
intake and 1-year. The proportions reporting each of these 
symptoms increased significantly between 1-year and  
3-years, thus the proportions between intake and 3-years 
were similar. The proportion reporting feeling fearful also 
increased between 1-year and 3-years, however the 
proportion reporting feeling fearful between intake and  
3-years did not change significantly.
In terms of depressive symptoms, there was a significant 
reduction in the proportion feeling lonely and the proportion 
having thoughts of ending their lives between intake and  
1-year, with these proportions more or less the same between 
1- and 3-years. The proportion at 1-year who reported 
experiencing feelings of worthlessness was significantly lower 
than at baseline. An increase in the proportion experiencing 
feelings of worthlessness, although not significant, was evident 
between 1- and 3-years. Finally, a significant reduction in the 
proportion feeling hopeless about the future was evident 
between intake and 3-years. Non-significant reductions in the 
proportion reporting feeling hopeless about the future were 
noted between intake and 1-year.
Table 11:  Number and proportion experiencing 
mental health symptoms at treatment intake,  
1-year and 3-years
Symptoms 
experienced 
over last 90 
days
Intake 1-year 3-years
% n % n % n
Anxiety symptoms
Feeling tense 65.3a 169 50.4ac 134 66.2c 184
Suddenly 
scared for no 
reason
34.6a 90 24.9ac 67 34.8c 98
Feeling 
fearful
42.8 107 35.1c 93 46.8c 131
Nervousness 
or shakiness 
inside
43.0a 110 32.8ac 87 41.9c 117
Spells of 
terror or 
panic
24.0 63 24.7 66 24.3 68
Depressive symptoms
Feeling 
hopeless 
about the 
future
57.1b 144 49.4 132 46.6b 131
Feeling of 
worthlessness
53.8a 136 42.2a 113 46.8 131
Feeling no 
interest in 
things
59.4 152 53.2 142 53.7 151
Feeling lonely 59.8ab 150 50.0a 132 49.1b 137
Thoughts of 
ending your 
life
25.9ab 64 17.9a 49 17.8b 50
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
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TREATMENT STATUS
Table 12 shows that 70% (n=201) of the per-protocol 
population was in some form of treatment at 3-years.  
Of these individuals, 86% (n=173) were in methadone 
treatment at 3-years.
Table 12:  Treatment status of participants at  
3-years
Current treatment status % n
In treatment at 3-years 70.0 201
Of those in treatment, proportion in 
methadone modality at 3-years
86.0 173
EMPlOyMENT AND TRAINING
Table 13 presents the proportions of individuals on training 
courses, currently employed, usually not working in the last 
three months, and employed at some time in the last three 
months as reported at treatment intake, 1-year and 3-years. 
Analysis revealed a significant increase in the proportion of 
clients undertaking training courses over the last six months 
between intake and 1-year, with further increases, although 
not significant, between 1-year and 3-years. The proportions 
currently employed and employed at some point in the last 
three months each increased slightly between intake and 1-year, 
and significant increases for each of these categories were noted 
between 1- and 3-years. Finally, there was a significant reduction 
in the proportion of clients who were usually unemployed over 
the last three months between intake and 1-year with further 
non-significant reductions between 1- and 3-years.
Table 13: Employment and training at treatment 
intake, 1-year and 3-years
Intake 1-year 3-years
% n % n % n
Training 
courses 
over last six 
months
14.9ab 43 29.2a 84 33.2b 96
Currently 
employed
15.0b 43 20.1c 58 31.3bc 90
Employed at 
some point 
in last three 
months
20.5b 58 22.1c 64 33.0bc 95
1Not working 46.5ab 133 35.6a 103 29.1b 84
1 Refers to participants’ usual occupations over the last three 
months i.e. what their employment status was for most of  
the time.
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
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ACCOMMODATION
Table 14 shows the participants’ accommodation over the 
previous three months as reported at treatment intake,  
1-year and 3-years. Analysis revealed a significant decrease 
in the proportion of participants who were living in the family 
home between intake and 1-year with further non-significant 
decreases noted between 1- and 3-years. These reductions 
were matched by increases in the proportion of candidates 
in their own house/flat or rental accommodation. Significant 
decreases were noted in the proportions in drug treatment 
residences between intake and 1-year with further significant 
reductions between 1- and 3-years. Finally, a significant 
reduction was found between the proportion in insecure 
tenure at intake and at 3-years.
Table 14: Accommodation at treatment intake,  
1-year and 3-years
1Accommodation 
over last 90 days
Intake 1-year 3-years
% n % n % n
Family home 48.4ab 135 34.6a 100 30.1b 87
Drug treatment 
residence
31.1ab 88 8.3ac 24 1.7bc 5
Own house/
flat or rental 
accommodation
37.1ab 105 45.7a 132 50.2b 145
Prison 8.5 24 8.3 24 8.3 24
2Insecure 
tenure
10.3 29 9.3 27 8.0 23
3Homeless 14.5b 41 12.1 35 10.0b 29
1 Categories not mutually exclusive 
2 Insecure tenure home of friends. 
3 Homeless includes participants living in hostels, shelters,  
B&B’s with no fixed abode.
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
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SERVICE CONTACT
Table 15 presents the medical and social support service 
contact for participants as reported at treatment intake,  
1-year and 3-years. In terms of medical service usage,  
there was a significant increase in the proportion visiting  
a non-methadone GP between intake and 1-year. Significant 
increases in the proportion attending a hospital and 
staying overnight, and the proportion visiting an out-patient 
department/receiving community treatment were evident 
between intake and 3-years.
In terms of social support service usage, significant increases 
were noted for proportions having contact with social services 
between intake and 1-year. Significant increases were also 
noted for both the proportion in contact with employment, 
training or education services and the proportion having 
contact about housing issues between intake and 1-year,  
as well as intake and 3-years. However, while the proportion 
having contact about employment, training or education 
increased significantly between intake and 3-years, the 
proportion having contact at 3-years was significantly lower 
than that at 1-year.
Table 15: Contact with services at treatment intake, 
1-year and 3-years
Services 
received  
in last 90 days
Intake 1-year 3-years
% n % n % n
Attended hospital 
and stayed 
overnight 
9.8a 28 11.1 32 15.9a 46
Attended 
Accident and 
Emergency
17.1 47 17.3 50 22.1 64
Visited a GP (not 
methadone GP) 
34.6a 91 46.0a 133 42.2 122
Visited an 
out-patient 
department/
received 
community 
treatment 
13.9a 38 20.1 58 22.1a 64
Social support 
contacts in last  
90 days
Had contact with  
social services 
6.1a 17 11.5a 33 10.4 30
Had contact 
about 
employment, 
training or 
education
10.0ab 26 42.9ac 123 30.8bc 89
Had contact 
about social 
welfare
32.3 86 28.9 83 26.4 76
Had contact 
about housing 
issues 
14.9ab 40 31.4a 90 27.0b 96
a  – matching ‘a’ denotes changes from intake to 1-year are 
statistically significant
b  – matching ‘b’ denotes changes from intake to 3-years are 
statistically significant
c  – matching ‘c’ denotes changes from 1-year to 3-years are 
statistically significant
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The per-protocol rate of 71.5% and the follow-up 
and interview rates of 97% and 88.4% respectively 
obtained at 3-years from the full cohort of 404 recruited, 
were exceptionally high by international standards. In 
comparison, the National Treatment Outcome Research 
Study (NTORS) in England and Wales decided at 4-5 
years to select a stratified random sub-sample of 650 
participants from a sample frame of 894 individuals 
extracted from the full original cohort of 1077 recruits. 
Despite the use of this smaller sub-sample, the follow-
up interview rate attained was 76.3% (496/650) 
(Gossop et al, 2003). ROSIE follow-up rates were 
also high in comparison with the Australian Treatment 
Outcome Study (ATOS), who achieved a follow-up 
interview rate of 76% (469/615) at 2 years (Darke 
et al, 2006). The achievement of a follow-up rate that 
is considerably higher than the international standard 
provides researchers with greater confidence in the final 
results observed for the ROSIE cohort at 3-years. 
Results observed for the per-protocol group reflected 
those observed for the full cohort at 3-years. Reductions 
in the proportions using a range of target drugs were 
sustained between 1- and 3-years. Similar results were 
observed in NTORS (Gossop et al, 2003) and ATOS 
(Darke et al, 2006). However, in addition, within the 
ROSIE study per-protocol cohort it was observed that 
the proportion, frequency and quantity of alcohol use 
decreased significantly between intake and 1-year and 
this decrease was sustained at 3-years. Results on 
cocaine use, including crack, reflected those observed for 
the full cohort. The reported use of cocaine powder and 
crack cocaine, when analysed as one variable, reduced 
significantly from intake to 1-year and this reduction was 
sustained at 3-years. 
In contrast to the sustained reductions observed above, 
the significant reduction in the use of benzodiazepines 
observed at 1-year within the ROSIE per-protocol 
cohort was not sustained at 3-years. In fact, a significant 
increase was observed in proportions using between 
1- and 3-years. That said, the proportion using at 3-years 
was still significantly lower than the proportion using at 
intake. This result was also observed for the full cohort.
Abstinence rates at 3-years within the ROSIE  
per-protocol and full cohorts were the same at 29.4%, 
despite differences at intake: the per-protocol group 
had an abstinence rate of 6.7%, while the full cohort 
intake abstinence rate was 9.3%. Per Comiskey, Kelly 
and Stapleton (2008), abstinence rates within NTORS 
were not directly comparable. This is often the case 
with international treatment outcome studies, due to 
differences in study design and methodology.
With regard to crime outcomes, the ROSIE per-protocol 
group reflected the full cohort and also reflected the 
outcomes observed in both NTORS and ATOS, with 
significant reductions in crime observed at 1-year being 
sustained at 3-years.
In terms of health, outcomes varied and no clear picture 
of health was observed. Within the per-protocol group, 
positive outcomes observed at 3-years in terms of 
significant reductions in poor appetite, feeling nausea, 
joint/bone pains, muscle pains and tremors/shakes were 
in line with those observed for the full ROSIE cohort. 
However, significant negative outcomes for tiredness/
fatigue and numbness/tingling were observed between 
1- and 3-years for the per-protocol group. Again within 
this group, it was observed that some anxiety symptoms 
decreased between intake and 1-year, but these 
significantly increased again from 1- to 3-years with 
levels returning to those observed at intake. With regard 
to depressive symptoms, the results were again mixed 
with some reductions sustained and some not. 
In summary, the results for the per-protocol group 
reflected those observed for the full ROSIE cohort. 
Results indicate that in Ireland treatment for opiate use 
has a positive and sustained effect not only on drug use 
but on alcohol use, drug related crime and on social 
functioning variables. While this is very encouraging, 
results for the physical and mental health symptoms 
continue to be mixed with no clear positive picture  
of health outcomes emerging either for the full or  
per-protocol group. Based on these findings, there is 
a need for further targeted research into the long-term 
impact of treatment for opiate use in Ireland on the 
health and well being of the individual. 
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